We're kicking off 2025 with a fantastic podcast episode featuring Katrin Jack, Global Access Strategy Head at Galderma and President of the Healthcare Businesswomen's Association Zürich-Zug Chapter.

This episode covers a lot of ground, from the 'sliding doors' moment that led Katrin into market access, to why she feels it's important for leaders to understand their core values (and stay true to them).

Like many of our podcast guests, Katrin has an obvious passion for market access and it was a delight to hear about her journey and the perspectives she's gained along the way.

Bonus: In addition to the many professional insights Katrin shares in this chat, she also references the following book: "Beginner with a Black Belt" by Ana Stevanović.

The opinions shared in this podcast are Katrin's own views.

In this episode we speak with Ezgi Erdogan who is Oncology Market Access Director for Emerging Markets at GSK.

In this discussion, we cover the unpredictability of emerging markets and the unique challenges this presents. Ezgi also shares her future predictions for access in emerging markets and talks about the importance of cross-functional collaboration in pharma to support the ever-changing landscape.

The opinions shared in this podcast are Ezgi's own views.

In this episode, we sit down with Pauline Payen, Director and Global Payer Strategy Lead for UCB’s Early Portfolio. Pauline shares her pragmatic insights into navigating the complexities of global market access.

Throughout her career, Pauline hasn't been shy of new opportunities, which has led to her taking on roles in commercial and marketing to expand her experience. In this discussion, we explore why market access is her passion. A field where, as she says, "What you do, can be life-changing for people."

Pauline describes the unique mindset essential for success in market access, as well as the importance of staying open to diverse opportunities along the way. It's an inspiring discussion on aligning personal values to professional growth.

The opinions shared in this episode are Pauline's own views.

In this episode we're joined by GSK's Head of Market Access for General Medicines, Rupert Gale.

Rupert has been in pharma for over 27 years and is still going strong! In this discussion, he shares what resilience means to him and why he feels it's an important skill for market access leaders to leverage.

Rupert shares some wonderful stories and advice that many of us can relate to and learn from. He also reveals what's keeping him passionate about access and value as he continues his career journey.

The views shared in this episode are Rupert's own opinions and not representative of the company he is working for.

Korinna Karampampa, who is Director Market Access and Pricing at CSL Behring, joins this episode to share her views on sustainable economic development.

Korinna shares what led her into market access and explains what drives her to think outside the box to build and demonstrate a product's current and future value.


The opinions shared in this episode are Korinna’s own views and not representative of the organisation she is working for.

In this episode we're joined by our first guest from Biotech - Ning Lu, who is Associate Director, International Pricing & Market Access at Blueprint Medicines.

Ning shares her views on the complexities of market access and what makes the Biotech industry unique. She shares what inspired her to pursue a career in market access in biotechnology and why she feels it's a dynamic role and opportunity to 'connect the dots' with everything you learn.

Ning references and recommends the book "Science Business: The promise. The reality. And the future of biotech." By Gary Pisano. More information on this title is available here. https://amzn.eu/d/5nfsQVA

The opinions shared in this episode are Ning’s own views and not representative of the organisation she is working for.

There’s no doubt that Market Access and Pricing leaders are fast becoming strategic partners in helping their wider organisations to understand the critical role of the function. In this episode, Marco Rauland from Merck KGaA joins us to explore this topic.

Marco is Vice President Global Market Access and Pricing strategy, Pricing and Analytics. With over 25 years' experience in the field, he shares his views on the importance of clear communication when engaging all stakeholders and why MA&P leaders need to take a holistic approach to understanding all corners of drug development and launch.

We also touch on the potential for AI in market access as the industry begins to explore the use cases of this latest innovation. Plus, the challenges market access leaders are facing and what strategies can help them overcome them.

The opinions shared in this episode are Marco’s own views and not representative of the organisation he is working for.

In this episode we're joined by Yvonne Hilsky who is Director of Market Access at Moderna. Having spent over 30 years in industry, Yvonne shares her views on what it takes to be successful in market access, including why making mistakes are an opportunity for growth.

Yvonne explores why it's important to have strong foundations and understand the 'building blocks' of market access and shares great stories from the early stages of her career, which we're sure will resonate with many of the market access community.